Alkermes plc. — Director's Dealing 2011

Sep 20, 2011

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Alkermes plc. (ALKS)
CIK: 0001520262
Period of Report: 2011-09-16

Reporting Person: HENWOOD GERALDINE (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2011-09-16	Non Qualified Stock Option (Right to Buy)	$23.61	A	10000	Acquired	2011-10-16	Common Stock (10000)	Direct
2011-09-16	Non Qualified Stock Option (Right to Buy)	$9.91	A	8000	Acquired	2013-04-24	Common Stock (8000)	Direct
2011-09-16	Non Qualified Stock Option (Right to Buy)	$9.91	A	20000	Acquired	2013-04-24	Common Stock (20000)	Direct
2011-09-16	Non Qualified Stock Option (Right to Buy)	$13.44	A	20000	Acquired	2013-09-09	Common Stock (20000)	Direct
2011-09-16	Non Qualified Stock Option (Right to Buy)	$11.84	A	20000	Acquired	2014-09-23	Common Stock (20000)	Direct
2011-09-16	Non Qualified Stock Option (Right to Buy)	$16.77	A	20000	Acquired	2015-09-23	Common Stock (20000)	Direct
2011-09-16	Non Qualified Stock Option (Right to Buy)	$14.04	A	20000	Acquired	2016-09-21	Common Stock (20000)	Direct
2011-09-16	Non Qualified Stock Option (Right to Buy)	$18.29	A	20000	Acquired	2017-10-09	Common Stock (20000)	Direct
2011-09-16	Non Qualified Stock Option (Right to Buy)	$11.44	A	20000	Acquired	2018-10-07	Common Stock (20000)	Direct
2011-09-16	Non Qualified Stock Option (Right to Buy)	$8.98	A	20000	Acquired	2019-10-06	Common Stock (20000)	Direct
2011-09-16	Non Qualified Stock Option (Right to Buy)	$14.92	A	20000	Acquired	2020-10-05	Common Stock (20000)	Direct

Footnotes

F1: These options are fully vested in accordance with their terms.

F2: Received in exchange for, and having substantially the same terms as, stock options of Alkermes, Inc. common stock in connection with the merger of Alkermes, Inc. and the global drug delivery technologies business of Elan (the "Merger").